Search Results - "Cohen, Calvin J"

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy by Grund, Birgit, Baker, Jason V, Deeks, Steven G, Wolfson, Julian, Wentworth, Deborah, Cozzi-Lepri, Alessandro, Cohen, Calvin J, Phillips, Andrew, Lundgren, Jens D, Neaton, James D

“…Despite effective antiretroviral treatment (ART), HIV-positive individuals are at increased risk of serious non-AIDS conditions (cardiovascular, liver and…”
Get full text

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial by Cohen, Calvin J, Dr, Andrade-Villanueva, Jaime, Prof, Clotet, Bonaventura, MD, Fourie, Jan, MD, Johnson, Margaret A, Prof, Ruxrungtham, Kiat, Prof, Wu, Hao, MD, Zorrilla, Carmen, MD, Crauwels, Herta, PhD, Rimsky, Laurence T, PhD, Vanveggel, Simon, MSc, Boven, Katia, MD

“…Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had…”
Get full text

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States by Sweet, Donna E, Altice, Frederick L, Cohen, Calvin J, Vandewalle, Björn

“…The possibility of incorporating generics into combination antiretroviral therapy and breaking apart once-daily single-tablet regimens (STRs), may result in…”
Get full text

Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial by Wayne, Peter M, Kiel, Douglas P, Buring, Julie E, Connors, Ellen M, Bonato, Paolo, Yeh, Gloria Y, Cohen, Calvin J, Mancinelli, Chiara, Davis, Roger B

“…Tai Chi (TC) is a mind-body exercise that shows potential as an effective and safe intervention for preventing fall-related fractures in the elderly. Few…”
Get full text

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease by Freedberg, Kenneth A, Losina, Elena, Weinstein, Milton C, Paltiel, A. David, Cohen, Calvin J, Seage, George R, Craven, Donald E, Zhang, Hong, Kimmel, April D, Goldie, Sue J

“…In the past decade, there have been dramatic changes in the treatment of human immunodeficiency virus (HIV) disease. 1 – 3 The use of combination…”
Get full text

Use of Genotypic resistance testing To guide HIV therapy: Clinical impact and cost-effectiveness by WEINSTEIN, Milton C, GOLDIE, Sue J, LOSINA, Elena, COHEN, Calvin J, BAXTER, John D, ZHANG, Hong, KIMMEL, April D, FREEDBERG, Kenneth A

“…Genotypic sequencing for drug-resistant strains of HIV can guide the choice of antiretroviral therapy. To assess the cost-effectiveness of genotypic resistance…”
Get full text

A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment by Liu, Wei, Zhang, Zhiwei, Hu, Zonghui, Xu, Ping, Cohen, Calvin J

“…In precision medicine, there is much interest in estimating the expected-to-benefit (EB) subset, i.e. the subset of patients who are expected to benefit from a…”
Get full text

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen by Lalezari, Jacob P., Bellos, Nicholaos C., Sathasivam, Kunthavi, Richmond, Gary J., Cohen, Calvin J., Myers, Robert A., Henry, David H., Raskino, Claire, Melby, Tom, Murchison, Hugh, Zhang, Ying, Spence, Rebecca, Greenberg, Michael L., DeMasi, Ralph A., Miralles, G. Diego

“…BackgroundT-1249 is a 39–amino acid synthetic peptide fusion inhibitor (FI) shown to preserve antiretroviral activity in vitro against human immunodeficiency…”
Get full text

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV by Cohen, Calvin J, Meyers, Juliana L, Davis, Keith L

“…Objectives Lower pill burden leads to improved antiretroviral therapy (ART) adherence among HIV patients. Simpler dosing regimens have not been widely explored…”
Get full text

Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial by Wayne, Peter M, Buring, Julie E, Davis, Roger B, Connors, Ellen M, Bonato, Paolo, Patritti, Benjamin, Fischer, Mary, Yeh, Gloria Y, Cohen, Calvin J, Carroll, Danette, Kiel, Douglas P

“…Post-menopausal osteopenic women are at increased risk for skeletal fractures. Current osteopenia treatment guidelines include exercise, however, optimal…”
Get full text

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials by COHEN, Calvin J, MOLINA, Jean-Michel, RIMSKY, Laurence, VANVEGGEL, Simon, WILLIAMS, Peter, BOVEN, Katia, CASSETTI, Isabel, CHETCHOTISAKD, Ploenchan, LAZZARIN, Adriano, ORKIN, Chloe, RHAME, Frank, STELLBRINK, Hans-Jürgen, TAISHENG LI, CRAUWELS, Herta

“…In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in…”
Get full text

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials by Cohen, Calvin J, Molina, Jean-Michel, Cahn, Pedro, Clotet, Bonaventura, Fourie, Jan, Grinsztejn, Beatriz, Wu, Hao, Johnson, Margaret A, Saag, Michael, Supparatpinyo, Khuanchai, Crauwels, Herta, Lefebvre, Eric, Rimsky, Laurence T, Vanveggel, Simon, Williams, Peter, Boven, Katia

“…BACKGROUND:Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. METHODS:Treatment-naive…”
Get full text

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study by van Lunzen, Jan, Antinori, Andrea, Cohen, Calvin J, Arribas, José R, Wohl, David A, Rieger, Armin, Rachlis, Anita, Bloch, Mark, Segal-Maurer, Sorana, Garner, Will, Porter, Danielle, Bosse, Matthew, Piontkowsky, David, Chuck, Susan K, De-Oertel, Shampa

“…OBJECTIVES:To compare efficacy, safety, tolerability, and patient-reported outcomes between two single-tablet regimens, rilpivirine/emtricitabine/tenofovir…”
Get full text

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment by Wilkins, Ed L., Cohen, Calvin J., Trottier, Benoit, Esser, Stefan, Smith, Don E., Haas, Bernhard, Brinson, Cynthia, Garner, Will, Chuck, Susan, Thorpe, David, De-Oertel, Shampa

“…This 96-week, randomized, open-label study was designed to assess the efficacy and safety of two single-tablet regimens in treatment naïve HIV-1-infected…”
Get full text

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1 : primary 24-week analysis by Nadler, Jeffrey P, Berger, Daniel S, Blick, Gary, Cimoch, Paul J, Cohen, Calvin J, Greenberg, Richard N, Hicks, Charles B, Hoetelmans, Richard M W, Iveson, Kathy J, Jayaweera, Dushyantha S, Mills, Anthony M, Peeters, Monika P, Ruane, Peter J, Shalit, Peter, Schrader, Shannon R, Smith, Stephen M, Steinhart, Corklin R, Thompson, Melanie, Vingerhoets, Johan H, Voorspoels, Ellen, Ward, Douglas, Woodfall, Brian

“…TMC125-C223 is an open-label, partially blinded, randomized clinical trial to evaluate the efficacy and safety of two dosages of etravirine (TMC125), a…”
Get full text

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy by COHEN, Calvin J, HUNT, Susan, RINEHART, Alex R, GRAHAM, Neil M, SENSION, Michael, FARTHING, Charles, CONANT, Marcus, JACOBSON, Susan, NADLER, Jeffrey, VERBIEST, Werner, HERTOGS, Kurt, AMES, Michael

“…To compare the effect of treatment decisions guided by phenotypic resistance testing (PRT) or standard of care (SOC) on short-term virological response. A…”
Get full text

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens by Swindells, Susan, Cohen, Calvin J, Berger, Daniel S, Tashima, Karen T, Liao, Qiming, Pobiner, Bonnie F, Snidow, Jerry W, Pakes, Gary E, Hernandez, Jaime E

“…Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors,…”
Get full text

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial by Cohen, Calvin J, Berger, Daniel S, Blick, Gary, Grossman, Howard A, Jayaweera, Dushyantha T, Shalit, Peter, Thompson, Melanie, Peeters, Monika, de Béthune, Marie-Pierre, Voorspoels, Ellen, Mack, Rebecca, Woodfall, Brian

“…Forty-eight-week results from a randomized, multicentre, part-blinded, phase IIb clinical trial assessing the efficacy and safety of 400 and 800 mg etravirine…”
Get full text

Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double-Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir) by Rhee, Martin S., Hellinger, James A., Sheble-Hall, Sandy, Cohen, Calvin J., Greenblatt, David J.

“…The relationship between plasma protease inhibitor (PI) trough concentrations and hyperlipidemic effects were evaluated retrospectively using data from 2 pilot…”
Get full text

Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids by Cohen, Calvin J

“…Ritonavir-boosted protease inhibitor (PI) regimens are beneficial in overcoming the development of resistance, providing durable virologic responses, and…”
Get full text